AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 20.43 USD -1.54%
Market Cap: 616.6m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

Intrinsic Value

ANAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ANAB stock under the Base Case scenario is 19.13 USD. Compared to the current market price of 20.43 USD, AnaptysBio Inc is Overvalued by 6%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ANAB Intrinsic Value
19.13 USD
Overvaluation 6%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AnaptysBio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ANAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ANAB?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about AnaptysBio Inc

Provide an overview of the primary business activities
of AnaptysBio Inc.

What unique competitive advantages
does AnaptysBio Inc hold over its rivals?

What risks and challenges
does AnaptysBio Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for AnaptysBio Inc.

Provide P/S
for AnaptysBio Inc.

Provide P/E
for AnaptysBio Inc.

Provide P/OCF
for AnaptysBio Inc.

Provide P/FCFE
for AnaptysBio Inc.

Provide P/B
for AnaptysBio Inc.

Provide EV/S
for AnaptysBio Inc.

Provide EV/GP
for AnaptysBio Inc.

Provide EV/EBITDA
for AnaptysBio Inc.

Provide EV/EBIT
for AnaptysBio Inc.

Provide EV/OCF
for AnaptysBio Inc.

Provide EV/FCFF
for AnaptysBio Inc.

Provide EV/IC
for AnaptysBio Inc.

Show me price targets
for AnaptysBio Inc made by professional analysts.

What are the Revenue projections
for AnaptysBio Inc?

How accurate were the past Revenue estimates
for AnaptysBio Inc?

What are the Net Income projections
for AnaptysBio Inc?

How accurate were the past Net Income estimates
for AnaptysBio Inc?

What are the EPS projections
for AnaptysBio Inc?

How accurate were the past EPS estimates
for AnaptysBio Inc?

What are the EBIT projections
for AnaptysBio Inc?

How accurate were the past EBIT estimates
for AnaptysBio Inc?

Compare the revenue forecasts
for AnaptysBio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of AnaptysBio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of AnaptysBio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of AnaptysBio Inc compared to its peers.

Compare the P/E ratios
of AnaptysBio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing AnaptysBio Inc with its peers.

Analyze the financial leverage
of AnaptysBio Inc compared to its main competitors.

Show all profitability ratios
for AnaptysBio Inc.

Provide ROE
for AnaptysBio Inc.

Provide ROA
for AnaptysBio Inc.

Provide ROIC
for AnaptysBio Inc.

Provide ROCE
for AnaptysBio Inc.

Provide Gross Margin
for AnaptysBio Inc.

Provide Operating Margin
for AnaptysBio Inc.

Provide Net Margin
for AnaptysBio Inc.

Provide FCF Margin
for AnaptysBio Inc.

Show all solvency ratios
for AnaptysBio Inc.

Provide D/E Ratio
for AnaptysBio Inc.

Provide D/A Ratio
for AnaptysBio Inc.

Provide Interest Coverage Ratio
for AnaptysBio Inc.

Provide Altman Z-Score Ratio
for AnaptysBio Inc.

Provide Quick Ratio
for AnaptysBio Inc.

Provide Current Ratio
for AnaptysBio Inc.

Provide Cash Ratio
for AnaptysBio Inc.

What is the historical Revenue growth
over the last 5 years for AnaptysBio Inc?

What is the historical Net Income growth
over the last 5 years for AnaptysBio Inc?

What is the current Free Cash Flow
of AnaptysBio Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for AnaptysBio Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
AnaptysBio Inc

Current Assets 448.7m
Cash & Short-Term Investments 430.1m
Receivables 12.2m
Other Current Assets 6.4m
Non-Current Assets 44.7m
Long-Term Investments 27.9m
PP&E 16.6m
Other Non-Current Assets 256k
Current Liabilities 43.9m
Accounts Payable 3.6m
Accrued Liabilities 40.3m
Non-Current Liabilities 365.2m
Other Non-Current Liabilities 365.2m
Efficiency

Earnings Waterfall
AnaptysBio Inc

Revenue
57.2m USD
Operating Expenses
-204.6m USD
Operating Income
-147.4m USD
Other Expenses
-18.2m USD
Net Income
-165.7m USD

Free Cash Flow Analysis
AnaptysBio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ANAB Profitability Score
Profitability Due Diligence

AnaptysBio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Declining ROE
Declining ROIC
17/100
Profitability
Score

AnaptysBio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

ANAB Solvency Score
Solvency Due Diligence

AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
54/100
Solvency
Score

AnaptysBio Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANAB Price Targets Summary
AnaptysBio Inc

Wall Street analysts forecast ANAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANAB is 54.77 USD with a low forecast of 23.23 USD and a high forecast of 94.5 USD.

Lowest
Price Target
23.23 USD
14% Upside
Average
Price Target
54.77 USD
168% Upside
Highest
Price Target
94.5 USD
363% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ANAB?

Click here to dive deeper.

Dividends

AnaptysBio Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ANAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

AnaptysBio Inc Logo
AnaptysBio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

631.4m USD

Dividend Yield

0%

Description

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Contact

CALIFORNIA
San Diego
10770 Wateridge Circle, Suite 210
+18583626295.0
www.anaptysbio.com

IPO

2017-01-26

Employees

102

Officers

President, CEO & Director
Mr. Daniel R. Faga
Chief Legal Officer
Mr. Eric J. Loumeau
Chief Medical Officer
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Financial Officer
Mr. Dennis M. Mulroy
Senior Vice President of Human Resources
Ms. Beth Mueller
Senior Vice President of Research
Dr. Martin Dahl Ph.D.
Show More
Chief Business Officer
Mr. Benjamin Stone
Senior Vice President of CMC
Mr. Douglas A. Rich M.B.A.
Senior Vice President of Corporate Affairs
Ms. Monique Da Silva
Senior Vice President of Clinical Operations
Ms. Priya Raina
Show Less

See Also

Discover More
What is the Intrinsic Value of one ANAB stock?

The intrinsic value of one ANAB stock under the Base Case scenario is 19.13 USD.

Is ANAB stock undervalued or overvalued?

Compared to the current market price of 20.43 USD, AnaptysBio Inc is Overvalued by 6%.

Back to Top